ライフサイエンスコーパス: PET

1 PET data were analyzed using plasma and reference tissue

2 PET histograms were almost always unimodal (94%, vs. 6%

3 PET imaging of tau pathology in Alzheimer disease may be

4 PET imaging was used to evaluate the whole-body distribu

5 PET imaging, biodistribution, autoradiography and immuno

6 PET pixel values within the region of interest for each

7 PET revealed impaired CVRC in 8 patients (44%).

8 PET was developed in the 1970s as an in vivo method to m

9 PET with (18)F-FDG captures neuronal activity that is in

10 PET-CT imaging shows a robust and specific PD-L1 signal

11 PET-CT is a powerful tool to evaluate the prognosis of d

12 PET/CT imaging was performed to visualize (18)F-FLT biod

13 PET/CT patients were discharged after imaging, whereas S

14 PET/CT results and SUVs were compared with prognostic fa

15 PET/CT using (18)F-FDG is an essential part of the manag

16 PET/CT was performed 21-25 (day 1) and 47-49 (day 2) h a

17 Results:(18)F-PSMA-1007 PET/CT had an NPV of 68% and an accuracy of 75%, and mpM

18 of 270 patients who underwent (68)Ga-PSMA-11 PET/CT at 4 institutions for BCR after prostatectomy wit

19 Post hoc analysis of (68)Ga-PSMA-11 PET/CT implied a major impact on SRT planning in 52 of 2

20 cal impact of additional late (68)Ga-PSMA-11 PET/CT.

21 h both (18)F-fluciclovine and (68)Ga-PSMA-11 PET/CT.

22 pecific membrane antigen 11 ((68)Ga-PSMA-11) PET/CT affects the implemented management of prostate ca

23 They all underwent [F-18]-AV-1451 PET imaging before death.

24 ions was associated with greater 18F-AV-1451 PET retention most prominently in the inferior temporal

25 the occurrence of categorized artifacts by 2 PET/MRI-experienced physicians.

26 JR11 is under clinical development as a PET imaging agent when labeled with (68)Ga ((68)Ga-NODAG

27 tive assessment of diaschisis performed by a PET neuroimaging specialist.

28 (Bmax) and biodistribution determination, a PET-specific structure-activity relationship (SAR) effor

29 ed (18)F-5-fluoroaminosuberic acid (FASu), a PET tracer that targets system xC(-) The goal of this st

30 fluoroazomycinarabinoside ((18)F-FAZA) is a PET biomarker for noninvasive identification of regional

31 (18)F-T807 is a PET radiotracer developed for imaging tau protein aggreg

32 924963 were successfully radiolabeled with a PET nuclide at high specific activity, radiochemical pur

33 s adnectin was labeled with (18)F to yield a PET radioligand for assessing PD-L1 expression in vivo.

34 um standard uptake value (DeltaSUVmax) after PET assessment was explored.

35 RI scans were obtained for 12 patients after PET/CT scans.

36 Although PET/CT with (68)Ga-PSMA-11 in the diagnosis of prostate

37 normal Abeta42 in the CSF and normal amyloid PET who subsequently convert to having abnormal CSF Abet

38 nce the use of CSF biomarkers and/or amyloid PET assessment in clinical practice and trials.

39 on selection is important for proper amyloid PET analysis, especially in subcortical vascular dementi

40 5 different immunoassays and visual amyloid PET analysis.

41 tivity MRI (fcMRI) in the context of amyloid-PET imaging.

42 Retrospective combination of mpMRI and PET/CT had an accuracy of 81% for total and 93% for near

43 formation that can be used to improve MR and PET image quality.

44 All patients underwent CXR/MRI, CCT/MRI, and PET/CT on the same day.

45 sualization in men using (68)Ga-NeoBOMB1 and PET/CT is also presented.

46 cer lesions in men using (68)Ga-NeoBOMB1 and PET/CT.

47 eting to precisely control arterial Pco2 and PET to measure the outcome variable, MBF.

48 eting PSMA have been developed for SPECT and PET platforms.

49 In the small-animal PET experiments, LNCaP tumors were clearly visualized.

50 On small-animal PET images, the tumor was clearly delineated soon after

51 Finally, small-animal PET imaging of an LNCaP tumor-bearing mouse was performe

52 re and after the 6 quantitative small-animal PET studies.

53 value was determined with the HEC method at PET imaging.

54 Overall, our results suggest granzyme B PET imaging can serve as a quantitatively useful predict

55 aggregates and have the potential to become PET tracers for future human use.

56 Correlations between PET uptake and semiquantitative immunohistochemical scor

57 F-florbetapir (Amyvid) is an amyloid-binding PET ligand with a half-life suitable for clinical use ou

58 cent introduction of simultaneous whole-body PET/MR scanners has enabled new research taking advantag

59 n low-molecular-weight PSMA ligands for both PET imaging and therapeutic approaches, with a focus on

60 as well as in vivo biodistribution and brain PET imaging studies in wildtype and mGluR2 knockout rats

61 s-3 HABs, 3 MABs, and 2 LABs-underwent brain PET imaging.

62 hort 1) or 3 (cohort 2) cycles of weekly BV; PET-negative patients (Deauville score </=2) proceeded t

63 isualized by (18)F-FDG uptake as detected by PET combined with CT.

64 75, H358 and H520 tumor-bearing nude mice by PET/CT imaging.

65 ide the detailed protocol for long-read ChIA-PET that includes cell fixation and lysis, chromatin fra

66 iginal approach by developing long-read ChIA-PET, in which the length of the paired-end tags is incre

67 The DRs of (18)F-choline PET/CT and multiparametric MRI were 56% and 74%, respect

68 ose within the acceptable range for clinical PET imaging agents and the potential for translation int

69 ng PDE4B-preferring radioligand for clinical PET imaging.

70 Lumbar spinal cord PET signal was significantly higher in EAE mice than in

71 Collection of CT, PET, and MR images along with outcomes from trials is cr

72 umans and to assess the ability of (64)CuCl2 PET/CT to detect prostate cancer (PCa) recurrence in pat

73 [(89)Zr]Zr-desferrioxamine (DFO)-daratumumab PET/CT imaging in MM tumor models.

74 [(89)Zr]Zr-DFO-daratumumab/PET demonstrated specificity and sensitivity for detecti

75 Measurements were performed to determine PET stability under varying MR conditions using the foll

76 gand (18)F-PSMA-1007 for use as a diagnostic PET tracer in prestaging and monitoring of prostate canc

77 ed with FB PET/CT followed by 20-second DIBH PET/CT.

78 Conclusion The DIBH PET/CT technique is feasible in routine clinical practic

79 We validated (68)Ga-DOTATATE PET as a novel marker of atherosclerotic inflammation an

80 (68)Ga-DOTATATE PET imaging was compared to [(18)F]FDG PET imaging in 42

81 (68)Ga-DOTATATE PET/CT in comparison to CE-MRI performed at a higher sen

82 (68)Ga-DOTATATE PET/CT resulted in intended management changes (Q2) in 4

83 ns or >/=5 y experience with (68)Ga-DOTATATE PET/CT; n = 3).

84 cans or <5 y experience with (68)Ga-DOTATATE PET/CT; n = 4) or a high level of experience (>/=500 sca

85 nknown primary site underwent (68)Ga-DOTATOC PET/CT in a single-site prospective study.

86 Conclusion:(68)Ga-DOTATOC PET/CT is an effective modality in the localization of u

87 d on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT scans, whereas an additional 68 lesions were foun

88 Dynamic PET data were analyzed using the validated two-tissue co

89 10 healthy subjects underwent 90-min dynamic PET.

90 We obtained dynamic PET recordings from brain of Spraque Dawley rats at base

91 spected Alzheimer disease) underwent dynamic PET imaging for up to 120 min after bolus injection of (

92 Through a systematic and cost-effective PET discovery process, involving expression level (Bmax)

93 ng the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failu

94 (95% confidence interval, 0.81-0.96) for EoT-PET.

95 A major impediment to expanding PET applications to study the brain has been the lack of

96 prospectively included and assessed with FB PET/CT followed by 20-second DIBH PET/CT.

97 lationship between metabolic activity at FDG PET in the residual lesion identified at brain MR imagin

98 Conclusion FDG PET/CT has satisfactory diagnostic accuracy in the detec

99 use of analysis of covariance, all (18)F-FDG PET brain images of MMF patients were compared with thos

100 (18)F-FDG PET identified intense inter-scapular BAT glucose uptake

101 (18)F-FDG PET imaging is routinely used to investigate brown adipo

102 on early evaluation of response by (18)F-FDG PET in patients in the Dutch GIST registry treated with

103 udies reporting the performance of (18)F-FDG PET or (18)F-FDG PET/CT in patients with suspected paran

104 rticle reviews the data evaluating (18)F-FDG PET quantification approaches in lung diseases, focusing

105 reproducibility of their impact on (18)F-FDG PET quantification in patients with non-small cell lung

106 his review focuses on recent human (18)F-FDG PET studies in Parkinson disease.

107 his study was to describe baseline (18)F-FDG PET voxel characteristics in pediatric diffuse intrinsic

108 tal of 13 articles (11 studies for (18)F-FDG PET-CT and 2 for LS), met the inclusion criteria.

109 When available,(18)F-FDG PET-CT may be preferred.

110 Conclusion:(18)F-FDG PET/CT after 1 treatment cycle is predictive of outcome

111 (18)F-FDG PET/CT can be considered a valuable tool for the work-up

112 and 77.8% on standard and delayed (18)F-FDG PET/CT for an SUVmax cutoff of greater than 1.32 and 1.8

113 recruited all those who underwent (18)F-FDG PET/CT for clinical reasons at our institution before in

114 ved with the control group or with (18)F-FDG PET/CT imaging.

115 vestigated the diagnostic value of (18)F-FDG PET/CT in chronic Q fever at diagnosis and during follow

116 he performance of (18)F-FDG PET or (18)F-FDG PET/CT in patients with suspected paraneoplastic syndrom

117 f all adult patients who underwent (18)F-FDG PET/CT in search of a focal source of infection was perf

118 Conclusion:(18)F-FDG PET/CT is a valuable technique for early detection of me

119 The use of (18)F-FDG PET/CT is mandatory to confirm a suspected diagnosis of

120 for early response evaluation with (18)F-FDG PET/CT performed most optimally for the prediction of re

121 nderwent a preoperative whole-body (18)F-FDG PET/CT scan at 1 h (standard examination) and an additio

122 ntil March 2015, when at least one (18)F-FDG PET/CT scan was obtained.

123 l, fourth and subsequent follow-up (18)F-FDG PET/CT scans resulted in change in management in 31.6% o

124 During follow-up, 57.3% of (18)F-FDG PET/CT scans resulted in treatment modification.

125 inal study population included 176 (18)F-FDG PET/CT studies in 153 patients (107 men, 46 women; age r

126 (18)F-FDG PET/CT studies were analyzed both qualitatively and semi

127 alitides, comparing the utility of (18)F-FDG PET/CT versus conventional brain imaging with MRI.

128 In multivariate analysis, (18)F-FDG PET/CT was the only factor independently associated with

129 n of (11)C-MET PET/CT with that of (18)F-FDG PET/CT.

130 nique was assessed in simultaneous (18)F-FDG PET/MR scans of a canine model of myocardial infarct and

131 Whole-body (18)F-FDG PET/MRI scans were obtained for 12 patients after PET/CT

132 ATATE PET imaging was compared to [(18)F]FDG PET imaging in 42 patients with atherosclerosis.

133 om various texture features on dual time FDG PET/CT images (DTPI) can differentiate between malignant

134 d temozolomide therapy and who underwent FDG PET/computed tomography because of radiologic deteriorat

135 ing DLBCL in the clinic; however, [(18)F]FDG-PET often faces difficulty in differentiating malignant

136 ose positron emission tomography ([(18)F]FDG-PET) imaging has an essential role in diagnosing DLBCL i

137 ormed a prospective multicenter study of FDG-PET/CT scanning 12 weeks after CCRT in newly diagnosed p

138 trate a relevant number of patients with FDG-PET false-negative MM and a strong association between h

139 Patients underwent (18)F-FDHT PET and (18)F-FES PET.

140 ers underwent a high-resolution [(18)F]FEPPA PET scan and MRI.

141 concordance between (18)F-FDHT and (18)F-FES PET and tumor AR and ER expression measured immunohistoc

142 Both (18)F-FHNP and (18)F-FES PET could clearly visualize the tumor in male mice beari

143 ients underwent (18)F-FDHT PET and (18)F-FES PET.

144 (18)F-FET PET might provide additional information beyond the tumo

145 es without prior local therapy and (18)F-FET PET scanning were retrospectively identified in 2 center

146 (2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET) PET.

147 A final PET quantitative stability assessment for simultaneous P

148 anned using an integrated 3-T time-of-flight PET/MRI system.

149 we evaluated the repeatability of (18)F-FLT PET as part of a multicenter trial involving patients wi

150 Thus, (18)F-FLT PET may be a useful tool to measure the severity of myel

151 went clinically indicated (18)F-fluciclovine PET/CT prior to enrollment.

152 underwent abdominopelvic (18)F-fluciclovine PET/CT, and the images were registered with the conventi

153 Motion correction of hybrid (18)F-fluoride PET markedly improves SNR, resulting in improved image q

154 ed by (18)F-fluoromisonidazole ((18)F-FMISO) PET and conventional and perfusion MRI before surgery.

155 For PET imaging of 18-kDa translocator protein (TSPO), a bio

156 s synthesized to incorporate fluorine-18 for PET imaging.

157 e attenuation-correction (AC) approaches for PET/MRI in clinical neurooncology.

158 ed the feasible application of (64)Cu(I) for PET imaging.

159 h(Hor)-dAph(Cbm)-Lys-Thr-Cys)-dTyr-NH2)) for PET imaging.

160 (68)Ga-pentixafor is a radiotracer for PET that binds with nanomolar affinity to CXCR4.

161 Current radiotracers for PET of hNIS expression are limited to (124)I(-) and (18)

162 cterize a specific small-molecule tracer for PET imaging that binds with high affinity to GPIIb/IIIa

163 ke value ratios (SUVRs) were calculated from PET scans and a mean global cortical SUVR was calculated

164 iogenesis and radiomic imaging features from PET/MRI.

165 The FTP-PET measures were computed as standardized uptake value

166 Human PET imaging using the second-generation TSPO radiotracer

167 In human PET studies, [(18) F]Nifene (185 MBq; <0.10 mug) was wel

168 2 (95% confidence interval, 0.73-0.91) for i-PET and 0.89 (95% confidence interval, 0.81-0.96) for Eo

169 and PETB) were reconstructed using identical PET emission data but with MR-AC from these intrasubject

170 Of the practical immuno-PET tracer modifications considered, glycosylation was t

171 It may thus be possible to use immuno-PET and monitor antitumor immune responses as a prognost

172 abolic tumor phenotypes that are captured in PET images, whereas KRAS-mutated tumors do not.

173 olysis, was significantly lower expressed in PET false-negative cases (5.3-fold change, P < .001) whi

174 nd 17 meaningful RSNs could be identified in PET and fMRI data, respectively.

175 egmentation of bones in CT and of lesions in PET.

176 -d-glucose ([(18)F]-FDG) is commonly used in PET/CT that is retained by metabolically active inflamma

177 The mean values of the initial PET/CT parameters in the LABC group were significantly h

178 patients were scanned twice on an integrated PET and MRI scanner.

179 le-body attenuation correction in integrated PET/MR scanners.

180 The specificity of interim PET/CT based on RIW criteria (61.5%) and Deauville crite

181 Event-free survival based on interim PET/CT (RIW) response was 93.3 +/- 4.1 versus 89.6 +/- 3

182 (68)Ga-PSMA ligand PET/CT enables discrimination of local versus metastatic

183 tate-specific membrane antigen (PSMA)-ligand PET imaging provides unprecedented accuracy for whole-bo

184 nd compared the biodistribution of (11)C-MET PET/CT with that of (18)F-FDG PET/CT.

185 ew Board-approved investigation of (11)C-MET PET/CT.

186 d at our institution for using a multiseries PET/CT acquisition technique that combines diagnostic-qu

187 All reconstructed 4D NAC PET images were then elastically registered to the singl

188 gistered to the single end-of-expiration NAC PET image.

189 No pre-NAC PET parameters predicted pTR.

190 After NaF PET for IS, there was claims agreement for planned surge

191 y reported that PET with (18)F-fluoride (NaF PET) for assessment of osseous metastatic disease led to

192 reported that PET using (18)F-fluoride (NaF PET) for assessment of osseous metastatic disease was as

193 Agreement was assessed between post-NaF PET intended management plans for treatment (surgery, ra

194 to assess the physical performance of a new PET/CT system, the Discovery IQ with 5-ring detector blo

195 This new PET strategy has great potential for early aGVHD diagnos

196 In subsequent non-human primate (NHP) PET imaging studies, [(18)F]8 showed rapid brain uptake

197 adiation dose from whole-body (11)C-nicotine PET imaging of 11 healthy (5 male and 6 female) subjects

198 Forty-nine PET/MRI brain scans were included: brain tumor studies u

199 (18)F-tetrafluoroborate ((18)F-TFB), a novel PET radioligand for imaging the human sodium/iodide symp

200 We designed novel PET imaging probes for the murine and human granzyme B i

201 mpared with diagnostic CT alone, addition of PET to diagnostic CT significantly increased sensitivity

202 Quantitative assessment of PET images was performed by volume-of-interest and ratio

203 Over the past years, a number of PET studies imaging the serotonin transporter (SERT) hav

204 he [18F]AV-1451 signal as seen on results of PET imaging is a valid marker of clinical symptoms and n

205 performance for central and site reviews of PET/CT images was calculated and receiver operating char

206 However, the risk of PET false-negative results in the presence of carbidopa

207 However, the role of PET during treatment (iPET) in daily practice remains a

208 A clinical imaging strategy based on PET/CT demonstrated a significantly higher detection rat

209 ries participating in the National Oncologic PET Registry (NOPR).

210 ncer participating in the National Oncologic PET Registry.

211 Conclusion:(68)Ga-pentixafor PET/CT is suitable for noninvasive, highly specific PET

212 We performed PET scans on mRCC patients with (89)Zr-bevacizumab, a VE

213 parametric images of dynamic (11)C-phenytoin PET studies was evaluated.

214 erity in either location did not predict PiB-PET.

215 quent longitudinal change in Abeta using PIB-PET imaging in cognitively normal older adults.

216 , which may, in turn, contribute to positive PET/CT and CT performances.

217 Posttreatment PET/CT (Deauville) predicts overall survival and has bet

218 high equipment and facility costs to produce PET probes, many radiopharmacies and radiochemistry labo

219 ve identified 8 (PF-06445974) as a promising PET lead.

220 /mL; range, 0.25-294 ng/mL), 362 (68)Ga-PSMA PET-positive lymph nodes (LNs) were identified.

221 Conclusion:(68)Ga-PSMA PET/CT altered management in 39% of patients with BCR, a

222 he association of intraprostatic (68)Ga-PSMA PET/CT findings and PSMA expression in immunohistochemic

223 Overall, (68)Ga-PSMA PET/CT scanning led to a change in planned management in

224 apeutic response according to follow-up PSMA PET.

225 (68)Ga-HBED-CC-Ahx-KuE ((68)Ga-HBED-CC-PSMA) PET/CT, allowing for their successful intraoperative det

226 y of within-suite (89)Zr-labeled radiotracer PET/CT-guided biopsy performed without reinjection.

227 ns for the highly selective sigma-1 receptor PET agent (18)F-6-(3-fluoropropyl)-3-(2-(azepan-1-yl)eth

228 A repeat PET/computed tomography demonstrated reduced size of the

229 The median time delay between research PET and surgery was 2 d.

230 xillary disease, and no significant residual PET avidity.

231 The observed (68)Ga-RM2 PET detection rate was 71.8%.

232 tative stability assessment for simultaneous PET scanning during functional MRI studies was performed

233 Su as a system xC(-) substrate is a specific PET tracer for functional monitoring of system xC(-) and

234 is suitable for noninvasive, highly specific PET imaging of CXCR4 expression in the atherosclerotic a

235 e in vivo kinetics of the novel tau-specific PET radioligand (18)F-AV-1451 in cognitively healthy con

236 imaging using [(18)F]-F-DPA, a TSPO-specific PET tracer.

237 s and relative diagnostic accuracy of SPECT, PET, and CCTA in detecting hemodynamically significant C

238 iggered widespread clinical interest in SSTR PET/CT throughout the United States.

239 In 4 of 14 studies, SSTR PET/CT was performed after an (111)In-Octreotide scan.

240 Efforts to standardize PET acquisition and reporting, including the 5-point Dea

241 te-specific membrane antigen (PSMA)-targeted PET/CT tracers, first (18)F-DCFPyL (2-(3-{1-carboxy-5-[(

242 a first look at the relationship between Tau-PET imaging with F(18)-AV1451 and functional connectivit

243 ide (ITO) coated polyethylene terephthalate (PET) electrode surface.

244 ndustries for preservative efficacy testing (PET).

245 We have previously reported that PET using (18)F-fluoride (NaF PET) for assessment of oss

246 We have previously reported that PET with (18)F-fluoride (NaF PET) for assessment of osse

247 The PET images matched ligand binding in post-mortem tissue,

248 ue of iMAR depends on the indication for the PET/CT scan, location and size/type of the prosthesis, a

249 n one or multiple reaction steps to form the PET tracer.

250 ty artifacts are then reconstructed from the PET emission data using the IPAC algorithm.

251 study was to evaluate whether SUVmax in the PET examination might correlate with semiautomated densi

252 tribution data confirmed the accuracy of the PET results, and histological analysis correlated high t

253 rformance with respect to the quality of the PET-CT images obtained.

254 asurements of LNs in the CT component of the PET/CT examination.

255 om scans, cold artifacts were visible on the PET image.

256 All subjects tolerated the PET/MRI examination well, and no adverse reactions to (1

257 d with ganciclovir-based preemptive therapy (PET).

258 These PET tracers can be synthesised either by late-stage radi

259 (PET) in an integrated time-of-flight (TOF) PET/magnetic resonance (MR) imaging system.

260 ron emission tomography/computed tomography (PET/CT) imaging with [(18)F]-fluorodeoxyglucose (FDG) ca

261 Combined positron emission tomography (PET) and computed tomography (CT) can assess both anatom

262 omen completed positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) sc

263 yglucose (FDG) positron emission tomography (PET) and hyperpolarized carbon 13 ((13)C)-pyruvate magne

264 consisting of positron emission tomography (PET) and magnetic resonance imaging (MRI) scans acquired

265 yglucose (FDG) positron emission tomography (PET) and survival in patients with glioblastoma and susp

266 ve males using positron emission tomography (PET) and the MOR-selective radioligand [(11)C]carfentani

267 TAC) for brain positron emission tomography (PET) in an integrated time-of-flight (TOF) PET/magnetic

268 Positron emission tomography (PET) is a powerful analytical tool for in vivo molecular

269 he method uses positron emission tomography (PET) of [(11)C]yohimbine binding in brain to quantify th

270 f heterocyclic positron emission tomography (PET) radioligands using the copper-mediated (18)F-fluori

271 ith long-lived positron emission tomography (PET) radionuclides, such as manganese-52 ((52)Mn, T(1/2)

272 sion by immuno-positron emission tomography (PET).

273 some form of photoinduced electron transfer (PET) quenching, which is diminished in the presence of s

274 c accumulation in TF-positive BXPC-3 tumors, PET imaging using (89)Zr-Df-ALT-836 promises to open new

275 Two PET images (PETA and PETB) were reconstructed using iden

276 All patients underwent PET/CT with (68)Ga-DOTA-E-[c(RGDfK)](2) radiotracer and

277 They underwent PET/CT after the administration of (68)Ga-THP-PSMA.

278 They underwent PET/CT imaging for the initial tumour staging and had no

279 better than that reported for commonly used PET TSPO tracers.

280 We used PET and [(11)C]raclopride to assess baseline DRD2 availa

281 We used PET and the mu-opioid-receptor (MOR)-specific ligand [(1

282 o image B cells in a mouse model of MS using PET.

283 M) of multiple sclerosis (MS) patients using PET.

284 has increased interest in theranostics using PET radionuclides with a relatively long physical half-l

285 ify and track platinum drugs in tumors using PET has the potential to translate into a clinically use

286 n of bone lesions at diagnosis by MRI versus PET-CT.

287 sures from different immunoassays and visual PET readings may influence the use of CSF biomarkers and

288 In vivo PET imaging showed specific uptake in PSMA-expressing tu

289 VMAT2 PET changed the diagnosis in 11 (23%) and medication in

290 ous stem cell transplantation (ASCT) whereas PET-positive patients received augICE before ASCT.

291 rding to a double baseline protocol in which PET examinations were repeated within 2 d of each other

292 investigated whether response assessed with PET/CT combined with baseline total metabolic tumor volu

293 well-known sources of error associated with PET/MRI examinations, lead to inconsistent SUV measureme

294 using (99m)Tc-tetrofosmin were compared with PET in the same patients.

295 levels of hypercapnia in healthy humans with PET.

296 mine transporter type 2 (VMAT2) imaging with PET allows assessment of the integrity of the presynapti

297 myocardial flow reserve (MFR) measured with PET have clinical value.

298 he complementary information obtainable with PET and MRI.

299 racer for investigating tumor perfusion with PET imaging.

300 (Q1) to indicate the treatment plan without PET/CT information, one immediately after review of the